search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Infection prevention


by 29.5% and CDI increased by 49.8% over the same broad period.6


The UKHSA HCAI dashboard


continues to show routine monthly surveillance across the major monitored pathogens, giving England a strong public-health data platform for infection-control analytics. England achieved a major reduction in CDI


after mandatory surveillance began in 2007, with incidence falling markedly in the following years. However, recent increases have renewed concern, and UKHSA-affiliated commentary has highlighted issues including recurrence burdens, changing epidemiology, and the emergence of novel ribotypes such as 955, associated with increased transmissibility, mortality and metronidazole resistance. For example., Novel Clostridioides difficile ribotype 955 (RT955) is a highly transmissible, hypervirulent strain that first emerged in the UK and has since been identified in several European nations. This demonstrates why modern IPC cannot rely only on past improvements; today’s practice requires systems capable of detecting changing patterns quickly and acting on them.


AI development: technical classes and intended functions Recent reviews indicate that AI in hospital IPC falls into five broad categories: predictive risk modelling, automated or semi-automated surveillance, computer vision or sensor-based behavioural monitoring, AMR and stewardship analytics, and early-warning tools for clinical deterioration linked to suspected HCAI. An integrative review in Frontiers in Public Health found that AI models frequently achieved strong performance for surgical-site infection (SSI) and urinary-tract infection applications,8


often with AUC values above 0.80, while a 2026 systematic review in the Journal of Hospital Infection highlighted a strong predominance of conventional machine-learning approaches such as decision trees, random forests and gradient boosting over more complex deep- learning systems.9 For hospital IPC, this emphasis on


conventional machine learning is logical. Many infection-control datasets are tabular, time- stamped and based on structured EHR elements such as medication exposure, microbiology, ward location and physiological measurements.10 These are well suited to models such as XGBoost, random forest and regularised logistic regression, which are comparatively easier to retrain, inspect and validate than more opaque architectures.11


Deep learning becomes more


relevant when free text, waveform data or video/depth-sensor streams are included – for example, in hand-hygiene monitoring or multimodal deterioration models. The UKHSA study on predicting future hospital


antimicrobial-resistance prevalence illustrates a particularly useful Trust-level AI application. Using historical data on antimicrobial use and resistance in bloodstream infections from English Trusts, investigators showed that XGBoost outperformed simpler forecasting methods, especially where resistance prevalence changed substantially. SHAP analyses demonstrated that the model was drawing on relationships across organisms and antibiotic classes, rather than simply projecting the same time series forward. In practical terms, this suggests that AI can help IPC and stewardship teams identify developing ecological pressures before resistance becomes entrenched.12


UK implementation landscape The UK implementation landscape is developing but still relatively early. In 2026, East Kent Hospitals University NHS Foundation Trust and the Royal Hospital for Neuro-disability announced deployment of an AI-enabled clinical decision-support tool, MEMORI, intended to help clinicians identify hospital-acquired infections earlier by analysing real-time patient data and notes embedded within the EPR.13


Related


reports describe the tool as explainable AI, designed to fit into existing workflows rather than sit alongside them, and state that further validation work is planned with Royal Devon University Healthcare NHS Foundation Trust through a collaboration involving Exeter HealthTech Research Centre.14 These deployments are noteworthy because


they move beyond academic prototyping into live NHS environments. However, the peer- reviewed effectiveness evidence remains thin. No robust published UK studies were identified demonstrating sustained reductions in Trust-level MRSA bacteraemia, CDI, Gram- negative bloodstream infection or HCAI- attributable mortality directly attributable to these deployed systems. This is consistent with the broader literature: the 2026 Journal of Hospital Infection review found that only a small minority of AI IPC studies had progressed to real-world implementation, and even fewer had demonstrated routine deployment with outcome reporting.9


Structuring data for AI-enabled infection control Data quality is central to trustworthy AI, particularly in IPC where outputs can lead to isolation, antibiotic changes, device removal or environmental escalation. In UK hospitals, a usable infection-control AI dataset typically draws from admission/discharge/transfer data, ward movement histories, vital signs, microbiology, laboratory chemistry, medication orders, procedure codes, device exposure, and free-text clinical notes. UKHSA’s surveillance systems for HCAI and SSI already provide standardised frameworks and case definitions that can support this work. Four data-engineering principles are


especially important. First, temporal integrity must be preserved so that models only use information available before the predicted event. Second, harmonised coding is required for wards, organisms, antibiotics and procedural descriptors. Third, feature provenance must be traceable so that users understand whether a predictor comes from validated microbiology, a medication chart or free-text inference. Fourth, ‘missingness’ must be handled intelligently,


20 www.clinicalservicesjournal.com I September 2026


TopMicrobialStock - stock.adobe.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85